XmAb942 (Xtend™ TL1A)
Novel high-affinity anti-TL1A antibody designed for extended half-life, under development for the treatment of patients with IBD
XmAb942 is a monospecific anti-TL1A antibody, utilizing Xencor’s Xtend™ Fc Domain and proprietary Fc silencing technology, with potentially class-leading potency, and is under development for patients with inflammatory bowel diseases (IBD). The two most common forms of IBD are Crohn’s disease and ulcerative colitis.
Half-life preclinically was greater than 22 days, potentially supporting an 8- to 12-week dosing regimen in humans. An abstract with preclinical characterization was accepted for presentation at the United Europe Gastroenterology Week (UEGW) in Vienna, Austria on Tuesday, October 15.
Xencor anticipates dosing the first subject in a first-in-human, single-ascending dose study of XmAb942 in the fourth quarter of 2024, with interim data during the first half of 2025. (Press Release, September 9, 2024)